Leading vitiligo researcher to join biotech innovators in improving treatment outcomes for
condition characterized by the appearance of white patches on skin.
TeVido BioDevices (TeVido), a pioneer in cellular therapy to treat loss of pigmentation, today announced the
appointment to the advisory board of Dr. John Harris, Director of the Vitiligo Clinic and Research Center at the
University of Massachusetts Medical School. Dr. Harris will leverage his extensive experience in the research,
diagnosis and treatment of vitiligo to help address significant unmet needs in reconstructive and cosmetic
procedures utilizing autologous cell therapy (using a patient’s own tissue) for patients with vitiligo as well as
nipple areola reconstruction for breast cancer survivors.
“TeVido’s mission has always been about helping patients to feel “whole” again,” said Laura Bosworth,
TeVido CEO. “As we developed our cell therapy techniques to re-pigment the nipple areola lost due to breast
cancer, we realized the procedure could benefit patients with vitiligo. Bringing Dr. Harris on our advisory board
will accelerate our development plan to make a meaningful difference in the lives of those suffering from
vitiligo, while we expand treatment options to include areola re-pigmentation and scarring.”
Vitiligo is a skin condition characterized by the appearance of white patches on any part of the body, such as
the face, hands and arms. There is no cure, and it can be psychologically devastating.
“I am excited to contribute to the meaningful work TeVido is doing in the area of vitiligo treatment,” said Dr.
Harris. “Vitiligo can cause severe emotional distress and social stigma. The ground-breaking techniques
TeVido will bring to market will have a profound impact on the quality of patients’ lives.”
Dr. John Harris, Advisor, is a key opinion leader in vitiligo and has multiple research publications and textbook
chapters on vitiligo. He serves on the Dermatology Foundation, Skin of Color Society, Global Vitiligo
Foundation, Vitiligo Research Foundation, and the American Academy of Dermatology. He is an advisor and
collaborator with AbbVie, Combe Inc, Genzyme/Sanofi, Stiefel/GSK, Aclaris Therapeutics, Celgene, and
Pfizer. He is an ad hoc reviewer on grant applications and for multiple research journals. He lectures on vitiligo
and other topics to local, regional, national, and international audiences.
Dr. Harris will be speaking on a panel with other vitiligo experts at World Vitiligo Day. The annual
international event that brings global awareness to this life-altering skin condition, will be held in Detroit,
Michigan on June 25th.
TeVido took 3rd place in The RESI Innovation Challenge, showcasing cutting-edge life science technologies in poster displays. The Redefining Early Stage Investments (RESI) Conference is for early stage life sciences companies to source investors, create relationships, and eventually, get funding.
Photo: Alejandro Zamorano, Director of Business Development, LSN | Laura Bosworth, CEO & co-founder, TeVido BioDevices | Scott Collins, CTO & VP of Research and Development, TeVido BioDevices | Michael Quigley, Director of Research, LSN.
CNBC and Singularity University invited some of the most exciting early stage companies in the world and brought them to Exponential Finance 2015 XCS Challenge. TeVido was named as a top 5 contender in the Health and Medicine category and had the opportunity to pitch at the event.
Watch CNBC Interview of CEO, Laura Bosworth
Springboard to a Healthier Future: TeVido BioDevices’ CEO and Co-Founder, Laura Bosworth, Joins Powerhouse Network of Women Entrepreneurial Leaders: 11 Companies Access Expert Network to Commercialize Disruptive Health Solutions
For over 15 years Springboard Enterprises has served as an on-ramp for over 550 of the most promising high tech companies led by women. The eleven (11) companies in the 2015 Health Innovation Hub class join the Springboard portfolio and will have ready access to Springboard’s vast expert network of corporate partners, industry experts, veteran entrepreneurs and investors. Read More
TeVido BioDevices won $25,000 in prize money at the Inaugural Texas New Ventures Competition, hosted by Texas A&M . The competition, which attracted more than 90 young companies, promoted the commercialization of emerging technology by recognizing companies with high growth potential. TeVido won two separate awards.